ERBB2 and breast carcinoma: NICE also recommends docetaxel monotherapy in patients with advanced breast cancer in whom anthracyclines have failed or are contraindicated, and in combination chemotherapy (e.g., with trastuzumab) in patients whose tumours overexpress human epidermal growth factor receptor 2 (HER2) (NICE, 2009b).